The medicine Tuksya containing Tucatinib is a tyrosine kinase inhibitor of HER2. In vitro, tucatinib inhibits phosphorylation of HER2 and HER3, inhibiting downstream MAPK and AKT signaling and cell proliferation, and showed antitumor activity in HER2-expressing tumor cells. Tuksya is available in 50 mg and 150 mg tablets for oral administration.
Healthcare professionals recommend this medicine for treating patients with advanced, unresectable, metastatic HER2-positive breast cancer and HER2-positive, unresectable, or metastatic colorectal cancer.
Breast cancer
Healthcare professionals recommend using Tukysa tablets combined with trastuzumab and capecitabine to treat patients with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases and who received one or more before anti-HER2-based regimens in the metastatic setting.
HER2-positive breast cancer happens when the cancerous cells have higher than normal protein levels called human epidermal growth factor receptor 2 (HER2). This protein is also in the breast tissue of people who don’t have breast cancer. HER2 helps breast cells grow and multiply. It also helps them repair the damage.
The recommended Tukysa dosage is 300 mg, taken twice daily orally with trastuzumab and capecitabine until disease progression or unacceptable toxicity.
Unresectable or Metastatic Colorectal Cancer
Healthcare providers use Tukysa 150 mg tablets to treat patients with RAS wild-type, HER2-positive unresectable, or metastatic colorectal cancer that has progressed in succeeding treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
Cancer cells might break away from a tumor in the colon or rectum and extend to other body parts via the bloodstream or lymphatic system. Such cells may settle and form new tumors on a different organ. Even though cancer has spread to a new organ, it is still named after the original part of the body. So colorectal cancer that spreads/ metastasizes to the lungs, liver, or other organs is called metastatic colorectal cancer, also known as stage 4 colorectal cancer.
The recommended dosage of Tukysa is 300 mg, taken twice daily orally in combination with trastuzumab until disease progression or unacceptable toxicity.
Note from The India Pharma
One should consult the doctor before taking the medicine Tukysa. And healthcare professionals should examine the patient for any medical history or other health-related casualties.